Clinical Trials in Pittsburgh

Showing 12021-12040 of 21,047 trials

Phase I/IIa Study of FIXFc in Hemophilia B Patients

NCT00716716

The primary objective of the study is to assess safety of FIXFc at doses ranging from 1 to 100 IU/kg.

Bioverativ Therapeutics Inc.10 participantsStarted Apr 2008

Chicago, Illinois, United States • Indianapolis, Indiana, United States • Boston, Massachusetts, United States +3 more locations

TERMINATEDPhase 2< 1 mile

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01266135

This study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of QAX576 in patients with idiopathic pulmonary fibrosis.

Idiopathic Pulmonary Fibrosis

Novartis Pharmaceuticals40 participantsStarted Dec 2010

Gainesville, Florida, United States • Orlando, Florida, United States • Boston, Massachusetts, United States +7 more locations

COMPLETEDPhase 1< 1 mile

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

NCT00880308

This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.

Advanced Solid Tumor CancersMedulloblastomaBasal Cell Carcinoma

Novartis Pharmaceuticals103 participantsStarted Mar 2009

Pittsburgh, Pennsylvania, United States • San Antonio, Texas, United States • Barcelona, Catalonia, Spain +2 more locations

Phase I/IIa Study of FIXFc in Hemophilia B Patients

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Find Trials by Condition in Pittsburgh

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

Dose Finding Study for QAW039 in Asthma

Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Efficacy, Safety, and Pharmacokinetics of QAW039

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

A Biobehavioral Intervention for Young Men With Testicular Cancer

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Helicobacter Pylori Genome Project (HpGP)

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

Effect of Hepatic Impairment on LDE225..

PCA062 in pCAD-positive Tumors.

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors